Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jul;194(1):65-72.
doi: 10.1016/j.juro.2015.01.091. Epub 2015 Jan 28.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men

Claire de la Calle  1 , Dattatraya Patil  1 , John T Wei  2 , Douglas S Scherr  3 , Lori Sokoll  4 , Daniel W Chan  4 , Javed Siddiqui  2 , Juan Miguel Mosquera  5 , Mark A Rubin  6 , Martin G Sanda  7
Affiliations
Multicenter Study

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men

Claire de la Calle et al. J Urol. 2015 Jul.

Abstract

Purpose: We evaluated the ability of PHI to discriminate aggressive prostate cancer from indolent or no cancer in a biopsy naïve population.

Materials and methods: Two independent prospective cohorts of 561 and 395 subjects, respectively, with no prior prostate biopsy who were enrolled at different clinical sites were used to validate the results. We compared the diagnostic specificity of PHI to prebiopsy total and percent free prostate specific antigen using prostate biopsy results. We also determined the optimal PHI threshold to discriminate aggressive prostate cancer (Gleason score 7 or greater) from indolent or no prostate cancer (Gleason score 6 or less).

Results: In the primary cohort higher PHI values were significantly associated with Gleason score 7 or greater. The AUC to detect aggressive prostate cancer was 0.815. At 95% sensitivity PHI specificity was 36.0% vs 17.2% and 19.4% for total and percent free prostate specific antigen, respectively. At 95% sensitivity for detecting aggressive prostate cancer the optimal PHI cutoff was 24, which would help avoid 41% of unnecessary biopsies. A cutoff of 24 led to 36% biopsies avoided with few aggressive cancers missed. These results were confirmed in the validation cohort.

Conclusions: The PHI detected aggressive prostate cancer with better specificity than total and percent free prostate specific antigen in a biopsy naïve population. It could be a useful tool to decrease unnecessary prostate biopsies.

Keywords: biopsy; nomograms; prostate; prostate-specific antigen; prostatic neoplasms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PHI results in patients with indolent (Gleason score less than 7) or no PCa and aggressive (Gleason score 7 or greater) PCa in primary (A) and validation (B) cohorts.
Figure 2
Figure 2
Optimal PHI score cutoffs by Gleason score 7 or greater in primary (A) and validation (B) cohorts. Solid curve represents sensitivity. Dashed curve represents specificity. Plus signs at bottom indicate data density. Vertical gray lines indicate PHI score at 95%, 90% and 80% sensitivity.
See this image and copyright information in PMC

References

    1. American Cancer Society®: Prostate Cancer, 2014. [Accessed June 8, 2014]; Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/index.
    1. Glass AS, Cowan JE, Fuldeore MJ, et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013;82:60. - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981. - PMC - PubMed
    1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239. - PubMed
    1. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876. - PubMed

Publication types

Substances